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ABSTRACT
Peritoneal dissemination as a manifestation of ovarian cancer is an adverse 
prognostic factor associated with poor clinical outcome, and is thus a potentially 
promising target for improved treatment. Sphere forming cells (multicellular 
spheroids) present in malignant ascites of patients with ovarian cancer represent 
a major impediment to effective treatment. p70 S6 kinase (p70S6K), which is a 
downstream effector of mammalian target of rapamycin, is frequently hyperactivated 
in human ovarian cancer. Here, we identified p70S6K as an important regulator for the 
seeding and successful colonization of ovarian cancer spheroids on the peritoneum. 
Furthermore, we provided evidence for the existence of a novel crosstalk between 
P-cadherin and β1 integrin, which was crucial for the high degree of specificity in cell 
adhesion. In particular, we demonstrated that the upregulation of mature β1 integrin 
occurred as a consequence of P-cadherin expression through the induction of the 
Golgi glycosyltransferase, ST6Gal-I, which mediated β1 integrin hypersialylation. 
Loss of p70S6K or targeting the P-cadherin/β1-integrin interplay could significantly 
attenuate the metastatic spread onto the peritoneum in vivo. These findings establish 
a new role for p70S6K in tumor spheroid-mesothelium communication in ovarian 
cancer and provide a preclinical rationale for targeting p70S6K as a new avenue for 
microenvironment-based therapeutic strategy.
INTRODUCTION
With approximately 200,000 new cases, and more 
than 125,000 related deaths occur each year worldwide, 
ovarian cancer is the most lethal of all gynecologic 
cancers [1]. The high rate of deaths is due to the large 
tumor burden with extensive peritoneal metastatic lesions. 
Despite initial chemosensitivity, ovarian cancer recurrence 
or peritoneal metastasis results in poor prognosis (<25%) 
and represents a serious clinical challenge. While 
it is known that localized peritoneal dissemination 
predominates over hematogenous or lymphatic spread, 
the exact mechanisms are still unknown. Successful 
adhesion on the peritoneal mesothelium represents a key 
rate-limiting step for the onset of the metastatic cascade. 
Unraveling the underlying molecular pathways is critical 
for developing new therapeutic strategies.
Emerging basic research, preclinical and clinical 
findings support the importance of p70 S6 kinase (p70S6K), 
a downstream effector of mammalian target of rapamycin 
(mTOR), in the progression of ovarian cancer [2]. 
Indeed, activation of mTOR is almost ubiquitous in 
ovarian carcinoma lesions and often correlates with 
poor prognosis [3]. p70S6K activation can result from the 
enhanced expression and activity of cytokines and growth 
factors, such as hepatocyte growth factor (HGF) that 
characterizes ovarian cancer [4]. p70S6K is activated more 
often in high-grade ovarian carcinomas, which highlights 
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the need to understand the role of p70S6K in ovarian cancer 
and disease progression [5]. Although the involvement of 
p70S6K in the control of growth has been well established, 
our recent studies showed for the first time that p70S6K 
could be involved in other aspects of tumor progression 
such as metastasis [4, 6]. However, we do not know 
if p70S6K plays a role during peritoneal adhesion and 
dissemination, and if so, how it regulates this process.
Cells propagated to form multicellular spheroids 
mimic most of the in vivo properties of tumors [7]. This 
is particularly relevant for ovarian cancer in view of the 
fact that tumor spheres commonly found in malignant 
ascites of ovarian cancer patients represent a significant 
impediment to efficacious treatment [8]. The observation 
that cancer stem/tumor-initiating cells can also be 
enriched by spheroids in suspension cultures further 
suggest spheroid cells may be associated with tumor 
aggressiveness [9]. Thus, cells cultured as 3D spheroids 
can be used as a tool to evaluate key metastatic events in 
the cascade.
Cadherins and integrins are major classes of cell 
surface receptors that mediate cell-cell and cell-matrix 
adhesion, respectively [7]. Cadherins, especially E-, N-, 
and P-cadherin have been implicated in the pathogenesis 
of ovarian cancer [8], and several integrins are expressed 
by ovarian tumor cells such as α2β1, α5β1, and αvβ3 [9]. 
However, the mechanistic basis of their crosstalk in 
ovarian cancer is not completely understood.
In this study, we show for the first time a role for 
p70S6K in the adhesion and metastatic spread of highly 
malignant ovarian cancer spheroids into the peritoneum. 
We also present evidence that a novel interplay linking 
P-cadherin to regulation of β1 integrin activation via the 
induction of the Golgi glycosyltransferase, ST6Gal-I, 
which mediates β1 integrin hypersialylation in this 
process.
RESULTS
p70S6K promotes ovarian cancer spheroid adhesion 
to peritoneal mesothelium
The first step in ovarian cancer metastasis is 
adhesion of cancer cells on the peritoneum. To investigate 
if p70S6K plays a role in influencing the adhesion of ovarian 
cancer cells to the peritoneum, we used a fluorescent-
based coculture assay to monitor the interactions between 
tumor spheroids and primary human mesothelial cells 
obtained from patients to model the in vivo condition of 
ovarian cancer. We first examined the intracellular level of 
p70S6K by Western blot analysis in three different human 
ovarian cancer cell lines (CaOV-3, OV-90, and OVCA429) 
(Figure 1A). CaOV-3 cells showed little expression of 
active p70S6K, whereas OV-90 and OVCA429 showed 
strong expression of active p70S6K. We then transfected 
constitutively activated p70S6K (myc-tagged D3E-E398) 
into CaOV-3 cells. Western blot analysis revealed that 
D3E-E398 increased p70
S6K activity, as indicated by an 
increase of phosphorylation of S6, a substrate of p70S6K 
(Figure 1B, inset). Importantly, ectopic expression of 
D3E-E398 significantly increased adhesion of CaOV-3 
spheroids to the mesothelial monolayer (Figure 1B). 
To confirm the importance of p70S6K in modulating 
mesothelial adhesion, we employed a small interfering 
RNA (siRNA) specifically engineered towards p70S6K. In 
these studies, HGF was used to activate p70S6K, because 
HGF is highly expressed in ascitic fluid of ovarian cancer 
patients, marking it as a major contributor to malignant 
spreading [10]. We and others have shown that Met 
tyrosine kinase, a high affinity receptor for HGF, is 
often overexpressed in ovarian carcinomas and cancer 
cell lines [4, 11], and constitutive activation of the Met 
receptor through paracrine/autocrine mechanisms has been 
observed with progressive neoplastic changes [11-13]. The 
effectiveness of p70S6K-specific siRNA, but not nonspecific 
siRNA, to deplete p70S6K expression was confirmed by 
Western blotting (Figure 1C, inset). Transfection of p70S6K 
siRNA in Met-expressing CaOV-3 spheroids inhibited 
the HGF-mediated adhesion to mesothelial cells (44% 
inhibition, P = 0.02) (Figure 1C) [4, 11]. We validated 
these results using an independent siRNA sequence 
targeting p70S6K. This effect was similar to the inhibition of 
cancer spheroid adhesion by rapamycin (40% inhibition, 
P = 0.041), a small molecule inhibitor of p70S6K kinase 
activity (Figure 1D). To complement our studies, we used 
two other independent cell lines, OV-90 and OVCA429, 
which have high basal p70S6K activities. Spheroid cells 
treated with p70S6K siRNA resulted in substantially 
decreased p70S6K phosphorylation (OV-90: 75% inhibition; 
OVCA429: 86% inhibition) and p70S6K expression 
(OV-90: 72% inhibition; OVCA429: 93% inhibition) 
(Figure 1E & 1F, inset). The siRNA treated OV-90 and 
OVCA429 spheroids with reduced p70S6K levels were 
incapable of effectively attaching to mesothelial cells, 
whereas nonspecific siRNA treated spheroids were 
unaffected (Figure 1E & 1F). These data suggest that 
p70S6K is an important mediator of ovarian cancer spheroid 
adhesion to the peritoneal mesothelium.
p70S6K activation enhances P-cadherin and β1 
integrin expression
To address the mechanism by which p70S6K signaling 
could influence cellular adhesion to the mesothelium, we 
investigated adhesion receptors peritoneal environment 
as a possible mechanism. We first determined whether 
p70S6K activation affected the expression of N- and 
P-cadherin present in the ovarian tumor/peritoneal 
microenvironment [8]. Although D3E-E398-expressing 
CaOV-3 showed increased expression of both N- and 
P-cadherin (Figure 2A), depletion of P-cadherin 
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Figure 1: p70S6K activation promotes cancer spheroid adhesion to human peritoneal mesothelial cells. (A) Whole cell 
lysates were analyzed for levels of phosphorylated (p-) and total p70S6K by Western blotting with β-actin was as the loading control. Signal 
intensity was determined by densitometry, and the level of p-p70S6K was normalized against total p70S6K. (B) Fluorescent-labeled CaOV-3 
spheroids transfected with empty vector or myc-tagged constitutively active p70S6K (D3E-E389) were plated onto a confluent mesothelium 
monolayer and allowed to adhere for 5 h. The percentage of adherent spheroids was quantified after nonadherent spheroids were removed. 
Whole cell lysates were analyzed for levels of phosphorylated (p-) and total S6 and myc by Western blotting (inset). CaOV-3 spheroids 
(C) expressing nonspecific (NS) or p70S6K siRNA or (D) pretreated with rapamycin (Rp; 20 nM) before stimulation with hepatocyte growth 
factor (HGF; 10 ng/ml) for 16 h were harvested for the adhesion assay with mesothelial cells. The activities of p70S6K were analyzed by 
Western blotting (inset).
(Continued)
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(Figure 2B, left), but not N-cadherin (Figure 2B, right), 
resulted in decreased adhesion of p70S6K-expressing cancer 
spheroids to the mesothelium, whereas treatment with 
nonspecific siRNA had no effect (Figure 2B). In addition, 
depletion of p70S6K in OVCA429 spheroids caused 
significant decreased P-cadherin expression and inhibited 
their adhesion to the mesothelium (Figure 2C & 2D). We 
also showed that spheroid-mesothelium adhesion was 
significantly increased in P-cadherin-overexpressing 
spheroids compared to control spheroids (~2-fold, 
P = 0.011), indicating this process was P-cadherin 
dependent (Figure 2E).
The extracellular matrix (ECM) underlying the 
mesothelium lies on an (ECM) rich in fibronectin, type 
I collagen, laminin, and vitronectin [14, 15]. Given the 
effect of p70S6K on adhesion to the mesothelium, we 
set out to assess if p70S6K could also affect adhesion 
of cancer spheroids to different ECM components in 
the peritoneal environment. Compared to empty vector 
expressing control spheroids, D3E-E398-expressing 
CaOV-3 spheroids had significantly enhanced adhesion 
to fibronectin (2.4-fold, P = 0.022) and laminin (1.4-fold; 
P = 0.049), but not to collagen I or vitronectin 
(Figure 3A). However, CaOV-3 spheroids treated 
with p70S6K siRNA almost completely inhibited 
HGF-mediated adhesion to fibronectin and laminin 
(Figure 3B), whereas treatment with nonspecific siRNA 
had no effect (Figure 3B). Furthermore, treatment with 
rapamycin also resulted in decreased spheroid attachment 
onto fibronectin and laminin (Figure 3C). In comparison, 
OV-90 and OVCA429 spheroids treated wtih p70S6K 
siRNA also showed marked decreases in adhesion 
to fibronectin (OV-90: 36% inhibition, P = 0.012; 
OVCA429: 36% inhibition, P = 0.045) and laminin 
(OV-90: 43% inhibition, P = 0.049; OVCA429: 
80% inhibition, P = 0.041), whereas treatment with 
nonspecific siRNA had no effect (Figure 3D & 3E).
β1 integrin is known to be relevant in the process 
of adhesion to fibronectin and laminin [16]. We found 
β1 integrin expression was significantly enhanced in 
D3E-E398-expressing CaOV-3 spheroids (Figure 4A, left), 
whereas knockdown of p70S6K resulted in decreased β1 
integrin expression (Figure 4A, right). Interestingly, 
these changes in expression occurred in the 130 kDa 
mature form of β1 integrin, which represents the fully 
glycosylated, functional receptor, but no changes 
occurred in the ~85-kDa core peptide (Figure 4A). 
To test the specific involvement of the mature form of 
β1 integrin more directly, we treated D3E-E398-expressing 
CaOV-3 spheroids with blocking antibodies against β1 
integrin. The inhibition of surface β1 integrin specifically 
inhibited the adhesion of spheroids to fibronectin, laminin 
(Figure 4B), and primary human mesothelial cells 
(Figure 4C). The inhibition of β1 integrin by specific 
siRNA treatment also inhibited 70S6K-dependent tumor 
spheroid attachment to fibronectin, laminin (Figure 4D), 
and mesothelial cells (Figure 4E). Similarly, β1 integrin 
siRNA-transfected OVCA429 showed significant 
reduction of spheroid adhesion to fibronectin, laminin 
(Figure 4F), and mesothelial cells (Figure 4G), which 
confirms the involvement of mature β1 integrin in ovarian 
cancer spheroid-mesothelium adhesion.
Figure 1: (E) OV-90 or (F) OVCA429 spheroids transfected with NS or p70S6K siRNA were used in the adhesion assay with 
mesothelial cells. The knockdown efficiencies of p70S6K were analyzed by Western blotting (inset). Data are expressed as 
mean ± S.D. *, P < 0.05; ***, P < 0.001 vs. control, empty vector or NS siRNA expressing spheroids.
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Figure 2: P-cadherin mediates p70S6K-dependent spheroid-mesothelium adhesion. (A) Whole cell lysates of CaOV-3 spheroids 
transfected with empty vector or myc-tagged constitutively active p70S6K (D3E-E389) were analyzed for levels of N- and P-cadherin by 
Western blotting with β-actin as the loading control. The signal intensity was determined by densitometry, and levels of N- and P-cadherin 
were normalized against the β-actin control. (B) Spheroids cotransfected with empty vector or myc-tagged D3E-E389 and nonspecific 
(NS) siRNA, P-cadherin siRNA (left) or N-cadherin siRNA (right) were plated onto a confluent mesothelium monolayer and allowed to 
adhere for 5 h. The percentage of adherent spheroids was quantified after nonadherent spheroids were removed. (C) The levels of p70S6K 
and P-cadherin in OVCA429 spheroids transfected with NS siRNA or p70S6K siRNA were analyzed by Western blotting. (D) OVCA429 
spheroids transfected with NS siRNA, N-cadherin siRNA, or P-cadherin siRNA, and (E) CaOV-3 spheroids stably expressing P-cadherin 
were harvested for the adhesion assay with mesothelial cells. The expression of P-cadherin was analyzed by Western blotting. Data are 
expressed as mean ± S.D. *, P < 0.05 vs. control, empty vector or NS siRNA expressing spheroids.
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Figure 3: p70S6K activation promotes spheroid adhesion to fibronectin and laminin. (A) CaOV-3 spheroids expressing 
empty vector or constitutively active p70S6K (D3E-E389) plasmid added to plates coated with collagen I, vitronectin, fibronectin, or laminin 
(10 μg/ml) for 2-5 h. (B) CaOV-3 cells expressing nonspecific (NS) siRNA or p70S6K siRNA or (C) pretreated with rapamycin (Rp; 
20 nM) before stimulation with hepatocyte growth factor (HGF; 10 ng/ml) were used in the adhesion assay with fibronectin or laminin. 
(D) OV-90 or (E) OVCA429 spheroids transfected with NS siRNA or p70S6K siRNA were used in the adhesion assay with fibronectin or 
laminin. The percentage of adherent spheroids was quantified after nonadherent spheroids were removed. Data are expressed as mean 
± S.D. *, P < 0.05 vs. control, empty vector or NS siRNA expressing spheroids.
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Figure 4: p70S6K regulates β1 integrin expression and regulates cancer spheroid-ECM adhesion. (A) Whole cell lysates of 
CaOV-3 spheroids transfected with empty vector or myc-tagged constitutively active p70S6K (D3E-E389) were analyzed for core or mature 
form of β1 integrin expression by Western blotting with β-actin as the loading control. The signal intensity was determined by densitometry 
and levels of the core or mature form of β1 integrin were normalized against the β-actin control. (B) Spheroids were preincubated with β1 
integrin neutralizing antibody (β1 integrin Ab) for the adhesion assay with fibronectin, laminin or (C) mesothelial cells. CaOV-3 spheroids 
cotransfected with empty vector or D3E-E389 and nonspecific (NS) siRNA or β1 integrin siRNA (β1 siRNA) were used in the adhesion assay 
with (D) fibronectin, laminin or (E) mesothelial cells. 
(Continued)
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P-cadherin functions upstream of β1 integrin in 
p70S6K signaling
To investigate the possible crosstalk between 
P-cadherin and β1 integrin and to determine their 
interdependency, we examined the effect of P-cadherin 
and β1 integrin siRNAs on the expression of the two 
adhesion receptors in D3E-E389-expressing CaOV-3 
spheroids. Knocking down β1 integrin did not affect 
P-cadherin expression (Figure 5A). However, depletion of 
P-cadherin did affect β1 integrin expression (Figure 5A), 
but only the expression of the mature β1 integrin was 
inhibited and not core β1 integrin (Figure 5A). For 
comparison, we also used OVCA429 spheroids, which 
gave us similar results (Figure 5B). Accordingly, treatment 
of CaOV-3 spheroids with P-cadherin siRNA abolished 
Figure 5: P-cadherin acts upstream of β1 integrin to mediate p70S6K-dependent adhesion. (A) CaOV-3 
spheroids cotransfected with constitutively active p70S6K (D3E-E389) and nonspecific (NS) siRNA, β1 integrin siRNA (β1 siRNA), or 
P-cadherin siRNA, and (B) OVCA429 spheroids transfected NS siRNA, β1 integrin siRNA, or P-cadherin siRNA were analyzed for core 
or mature forms of β1 integrin and P-cadherin by Western blotting with β-actin as the loading control. The signal intensity was determined 
by densitometry, and levels of P-cadherin and the core or mature forms of β1 integrin were normalized against the β-actin control.
Figure 4: OVCA429 spheroids transfected with NS siRNA or β1 integrin siRNA were used in the adhesion assay with (F) fibronectin, 
laminin or (G) mesothelial cells. The knockdown efficiencies of β1 integrin were evaluated by Western blotting (inset). The percentage of 
adherent spheroids was quantified after nonadherent spheroids were removed. Data are expressed as mean ± S.D. *, P < 0.05; **, P < 0.005 
vs. empty vector or NS siRNA expressing spheroids.
(Continued)
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Figure 5: (C) D3E-E389-expressing CaOV-3 or (D) OVCA429 spheroids transfected with NS siRNA or P-cadherin siRNA 
were used in the adhesion assay with fibronectin or laminin. (E) CaOV-3 stably expressing P-cadherin were analyzed 
for core or mature forms of β1 integrin by Western blotting with β-actin as the loading control. P-cadherin-expressing 
CaOV-3 transfected with NS siRNA or β1 integrin siRNA were collected for the adhesion assay with (F) fibronectin, laminin 
or (G) mesothelial cells. The percentage of adherent spheroids was quantified after nonadherent spheroids were removed. Data 
are expressed as mean ± S.D. *, P < 0.05; **, P < 0.005; ***, P < 0.001 vs. empty vector or NS siRNA expressing spheroids.
D3E-E389-mediated adhesion to fibronectin and laminin 
(Figure 5C), and again similar results were observed with 
OVCA429 spheroids (Figure 5D). Ectopic expression 
of P-cadherin significantly increased the levels of the 
mature β1 integrin, but not core β1 integrin (Figure 5E). 
After transfection with β1 integrin siRNA, P-cadherin-
overexpressing CaOV-3 spheroids were unable to adhere 
to fibronectin, laminin (Figure 5F), and mesothelial 
cells (Figure 5G). The nonspecific siRNA treatment 
had no effect. Together, these observations raise the 
intriguing possibility that P-cadherin could affect the 
posttranslational events of β1 integrin, and subsequently 
its activity in ovarian cancer cells.
N-glycans of β1 integrin are known to have 
a different carbohydrate compositions after cell 
transformation [17]. Recent studies suggest that β1 integrin 
is a substrate for the Golgi glycosyltransferase, ST6Gal-I 
[18, 19]. To investigate more in detail the regulation of 
β1 integrin by P-cadherin, we tested the involvement of 
ST6Gal-I. A strong induction of ST6Gal-1 was observed 
in p70S6K-expressing CaOV-3 spheroids (Figure 6A), 
which was markedly reduced with P-cadherin siRNA 
treatment, but nonspecific siRNA treatment had no effect 
(Figure 6B). In support, knockdown of p70S6K (Figure 6C) 
or P-cadherin (Figure 6D) in OVCA429 significantly 
inhibited ST6Gal-I expression, whereas overexpression 
of P-cadherin in CaOV-3 enhanced ST6Gal-I expression 
(Figure 6E). The knockdown of ST6Gal-I significantly 
inhibited the P-cadherin-induced mature β1 integrin 
expression (Figure 6F), indicating that ST6Gal-I was 
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Figure 6: p70S6K–P-cadherin signaling regulates β1 integrin maturation through ST6Gal-I. CaOV-3 spheroids were 
transfected with (A) constitutively active p70S6K (D3E-E389) alone or (B) cotransfected with nonspecific (NS) siRNA or P-cadherin siRNA. 
OVCA429 spheroids were transfected with NS siRNA, (C) p70S6K siRNA, or (D) P-cadherin siRNA. (E) CaOV-3 spheroids were stably 
transfected with P-cadherin. Total RNA was extracted and RT-PCR was carried out with the primer specific to ST6Gal-I. β-actin served as 
the control. Signal intensity was determined by densitometry and levels of ST6Gal-I were normalized against the β-actin control. CaOV-3 
spheroids stably expressing P-cadherin were transfected with NS siRNA or ST6Gal-I siRNA. (F) The level of mature form of β1 integrin in 
whole cell lysates was analyzed by Western blotting. The knockdown efficiency of ST6Gal-I siRNA was analyzed by RT-PCR (insert). In 
addition, spheroids were collected for the adhesion assay with (G) fibronectin, laminin or (H) mesothelial cells. The percentage of adherent 
spheroids was quantified after nonadherent spheroids were removed. Data are expressed as mean ± S.D. *, P < 0.05 vs. control, empty 
vector or NS siRNA expressing spheroids.
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involved in this process. These data indicate P-cadherin 
plays a role in the increased expression of ST6Gal-I 
by p70S6K activation. Using spheroid adhesion assays, 
we further showed that α2-6 sialylation of β1 integrin 
was required for the P-cadherin-mediated adhesion to 
fibronectin, laminin (Figure 6G), and mesothelial cells 
(Figure 6H).
P-cadherin-dependent ST6Gal-I induction is 
mediated by p120 catenin (p120ctn)
To determine how P-cadherin interacts with 
ST6Gal-I at the molecular level, we evaluated the 
potential contributions of β-catenin and p120ctn, which are 
associated with the intracellular domain of P-cadherin and 
are known to affect gene expression. We used siRNAs to 
knockdown β-catenin and p120ctn expression in P-cadherin-
overexpressing CaOV-3 spheroids. Knockdown of 
p120ctn (Figure 7A, left), but not knockdown of β-catenin 
(Figure 7A, right), dramatically reduced the expression of 
mature β1 integrin in P-cadherin-overexpressing CaOV-3 
spheroids. Knockdown of p120ctn expression prevented 
the upregulation of ST6Gal-I in response to P-cadherin 
(Figure 7B). In OVCA429 spheroids, knockdown of 
p120ctn, but not knockdown of β-catenin, had similar 
effects on β1 integrin (Figure 7C) and ST6Gal-I 
(Figure 7D) expression. In addition, we observed an 
increased level of p120ctn in D3E-E389- (Figure 7E) and 
P-cadherin-expressing CaOV-3 spheroids (Figure 7F), but 
silencing of P-cadherin abolished this (Figure 7G). These 
results show the P-cadherin-ST6Gal-I interaction was 
mediated by canonical p120ctn signaling.
Figure 7: P-cadherin-ST6Gal-I dependent β1 integrin maturation is mediated by p120ctn. CaOV-3 spheroids stably 
expressing P-cadherin or OVCA429 spheroids were transfected with nonspecific (NS) siRNA, p120ctn siRNA, or β-catenin siRNA. 
(A, C) The level of the mature form of β1 integrin in whole cell lysates was analyzed by Western blotting. (B, D) Total RNA was extracted 
and the level of ST6Gal-I was analyzed by RT-PCR. 
(Continued)
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p70S6K inhibition reduces adhesion and 
peritoneal metastasis
The data so far indicate that β1 integrin is 
upregulated by P-cadherin upon p70S6K activation and 
to induce adhesion in vitro. We further investigated the 
interplay between p70S6K, P-cadherin, and β1-integrin in 
the metastatic process in ovarian cancer. We examined 
the effect of p70S6K, P-cadherin, and β1 integrin shRNA 
on ovarian cancer spheroids growth in the peritoneal 
cavity using an orthotopic mouse model with advanced 
ovarian cancer [20]. Control mice or nonspecific shRNA-
treated mice showed multiple tumors on the omentum, 
mesenterium and small bowel (Figure 8). The tumor 
burden as gauged by the number of disseminated tumor 
nodules was significantly fewer in mice injected with 
p70S6K (62.6% inhibition, P = 0.024), P-cadherin (73.5% 
inhibition, P = 0.047), and β1 integrin (54.2% inhibition, P 
= 0.021) shRNA-expressing spheroids. These in vivo data 
further support the importance of a p70S6K-P-cadherin-β1 
integrin signaling axis in ovarian cancer metastasis.
DISCUSSION
Understanding the early steps of metastasis is 
crucial to identify novel targets for cancer therapeutics. 
Peritoneal metastasis is a lethal progression of ovarian 
cancer, and determining the molecular mechanisms 
involved is a pressing need. Here for the first time, we 
provide evidence that p70S6K, a key intracellular signaling 
mediator of multiple growth factors in malignant ascites 
and is frequently activated in human ovarian cancer, 
plays a critical role in adhesion of ovarian cancer cells to 
the peritoneal mesothelium, which is one of the earliest 
steps in metastasis. This would suggest that p70S6K might 
be as important in tumor progression as other very early 
genetic abnormalities, which could be targeted for cancer 
treatments. These types of treatment would be intriguing 
because current targeted therapies for ovarian cancer focus 
on counteracting the progression (e.g. vascular endothelial 
growth factor or angiogenesis) rather than the initiation of 
metastasis.
We also demonstrated a new mechanism of 
action of p70S6K in peritoneal adhesion, which involved 
P-cadherin and β1 integrin as targets. This observation 
also expands on our previous findings. We previously 
detected significant levels of P-cadherin in the metastatic 
adenocarcinoma in omentum or peritoneum and on 
mesothelial cells, suggesting that P-cadherin may mediate 
tumor-mesothelial cell adhesion [21]. This function 
could be explained by the fact that P-cadherin is the 
predominant subtype expressed in the peritoneum and by 
the unique ability of cadherins to engage in homophilic 
(i.e., between the same cadherins) and heterotypic (i.e., 
between two different cell types) interactions [22, 23]. The 
involvement of β1 integrin in ovarian tumorigenesis has 
also been supported by several studies [24]. Clinically, 
high β1 integrin expression is indicative of a poor outcome 
[25]. Treatment with a β1 integrin antibody either before 
disseminated tumors develop or after solid tumors are 
Figure 7: Whole cell lysates of CaOV3 spheroids (E) expressing empty vector or constitutively active p70S6K (D3E-E389), or 
(F) stably expressing P-cadherin, or (G) coexpressing D3E-E389 with NS or P-cadherin siRNA were analyzed for the level 
of p120ctn by Western blotting. β-actin served as the control for both Western blotting and RT-PCR. Signal intensity was 
determined by densitometry and levels of the mature form of β1 integrin, ST3Gal-I or p120ctn were normalized against the 
β-actin control. Data are expressed as mean ± S.D. *, P < 0.05; **, P < 0.005; ***, P < 0.001 vs. empty vector or NS siRNA 
expressing spheroids.
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established within the peritoneal cavity have been shown 
to be effective in inhibiting ovarian cancer metastasis [26]. 
In addition to their involvement in the adhesion of ovarian 
cancer cells to peritoneal mesothelial cells, it is important 
to emphasize that both P-cadherin and β1 integrin may 
activate ‘outside-in signaling’ to stimulate subsequent 
migration and invasion [27, 28].
The existence of interplay between members 
of different families of adhesion molecules has been 
previously suggested in other cellular systems. For 
example, N-cadherin expression stimulates directional 
and collective cell migration by activating integrins [29]. 
Likewise, in squamous carcinoma cells, the signaling 
pathway between T-cadherin and β1 integrin is important 
for aggressive invasion and distant metastasis [30]. The 
biological implication of this crosstalk in ovarian cancer 
is potentially of high functional significance because 
this fine-tuned mechanism ensures efficient coordination 
between adhesion systems, where spatial and temporal 
coordinated expression and activation of multiple 
receptors are more important for regulating cell adhesion 
than the intrinsic specificity of individual receptors 
[31-33]. In particular, expression of β1 integrin could give 
ovarian cancer cells a selection advantage that allows 
them, upon displacement of the mesothelial cells, to attach 
to the underlying ECM. The expression of P-cadherin 
induces cell-matrix adhesion, which is consistent with 
the hypothesis that cadherins are master regulators of cell 
adhesion and are required for establishing diverse cell 
junctions [34].
One of the novel findings of the present study is 
that P-cadherin was shown to be an activator of ST6Gal-I 
synthesis. In many tissues or cell type, ST6Gal-I is 
differentially expressed. This suggests that the gene 
expression of ST6Gal-I could be controlled by specific 
promoters or corresponding transcriptional factors of 
the oncogene and tumor suppressor pathways to regulate 
ST6Gal-I expression [35]. For example, the Ras oncogene, 
liver-enriched factors HNF-1 and DBP, and transcription 
factors AP-1 and AP-2 have all been reported to participate 
in the transcriptional activity of ST6Gal-I [36-38]. This 
study is the first to demonstrate that ST6Gal-I is a target 
gene of P-cadherin, adding P-cadherin as a new member 
of transcriptional modulators of ST6Gal-I.
Our findings provide the first evidence of the 
crosstalk between P-cadherin and β1 integrin is based 
Figure 8: Inhibition of p70S6K-P-cadherin-β1 integrin signaling reduces peritoneal metastasis in vivo. (A) Female NOD 
SCID mice were injected intraperitoneally with 1x107 OVCA429 cells (obtained from spheroid cultures) transduced with nonspecific (NS) 
shRNA, p70S6K shRNA, P-cadherin shRNA, and β1 integrin shRNA. They were sacrificed 15 weeks after injection. Representative views of 
the metastases in the peritoneal cavity are shown. Arrows indicate tumor. (B) Tumors were counted at autopsy. Data are expressed as mean 
± S.D. *, P < 0.05 vs. NS shRNA expressing spheroids.
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on the regulation of β1 integrin activation that occurs 
at the post-translation modification level. The rapidity 
with which β1 integrin becomes activated could be the 
mechanism by which ovarian cancer cells can specifically 
and rapidly respond to environmental changes. Although 
mechanisms have not been fully elucidated, α2-6 
sialylation could modify integrin-dependent cell responses 
by changing receptor conformation or by indirect 
mechanisms with other membrane-associated proteins 
[17]. Of interest, ST6Gal-I is overexpressed in many types 
of cancers including ovarian cancer and this upregulation 
correlates with increased metastatic potential and poor 
prognosis [39-41].
The experiments in this study examined spheroids 
that closely mimic conditions in vivo and could be of 
clinical importance. Increasing evidence indicates that 
ovarian carcinoma cells cultured as spheroids exhibit 
different proliferative and adhesive properties compared 
to monolayer cultures [42, 43]. Our results suggest 
that targeting p70S6K could provide the best approach 
to inhibiting the progression of ovarian cancer in its 
initial stage, including ovarian carcinomas that may 
be localized in the ovary but have malignant ascites or 
positive peritoneal washings, and also that have not been 
completely removed during surgery at the microscopic 
level.
Many inhibitors that target the mTOR/p70S6K 
pathway have been developed and some are currently 
being tested in clinical trials. For example, RAD001 
(Everolimus) has been shown to be effective in delaying 
tumor progression and prolonging survival in both 
xenografts and transgenic mice models of ovarian cancer 
[44, 45]. CCI-779 (Temsirolimus) tested in patients with 
malignant ovarian cancer resulted in the apparent reduction 
of ascites and decreased peritoneal dissemination of tumor 
cells [46]. NVP-BEZ235 could effectively inhibit growth 
of ovarian cancer cells even with platinum resistance 
and could prolong survival of mice with intraperitoneal 
ovarian tumors [47]. Furthermore, rapamycin and several 
of its analogs have been demonstrated to have synergistic 
cytotoxic effect with other chemotherapeutic agents on 
ovarian cancer [45, 48, 49]. Recent evidence suggests that 
mTOR/p70S6K signaling is overactivated in p53 deficient 
or mutant cells [50-52]. Alterations in p53 are common 
in advanced ovarian cancer [53]. The diverse types 
of p53 mutants make it difficult to develop a versatile 
p53-reactivating drug, but targeting the mTOR/p70S6K 
pathway could be an alternative strategy. Detailed tumor 
intervention studies and survival analyses on ovarian 
cancer treatments targeting this pathway certainly merit 
further investigation.
In summary, our study provides new findings 
show that p70S6K increases peritoneal adhesion and 
dissemination of ovarian cancer. Our observation that 
activation of P-cadherin/β1 integrin crosstalk promotes 
peritoneal metastasis of ovarian cancer indicates this 
signaling pathway could play a role in ovarian cancer 
malignancy. Because patient’s prognosis depends on the 
tumor residue, it is critical to understand the molecular 
events that regulate metastasis. Our results should be a 
step in this direction and provide a strong rationale to 
explore the targeting of p70S6K in the context of novel 
strategies against ovarian cancer dissemination.
MATERIALS AND METHODS
Cell lines and cell culture
Human ovarian CaOV-3 (a gift from Dr. Nelly 
Auersperg, University of British Columbia, Vancouver, 
B. C., Canada), OV-90 and OVCA429 cancer cell lines 
were maintained in M199:MCDB105 supplemented with 
5% fetal bovine serum (Hyclone, Logan, UT, USA) at 
37oC under 5% CO2. To generate spheroids, cells were 
dissociated by trypsinization and plated on non-adhesive 
culture dishes as described [54]. Spheroids were collected 
for experiments after 36 to 48 h. Each spheroid was about 
100 μm in diameter containing about 500-1,000 cells. 
Human peritoneal tissue was obtained from patients 
undergoing surgery for benign conditions. Mesothelial 
cells were isolated as described [55], and were cultured at 
37oC for 2 to 3 days until a monolayer of polygonal cells 
had grown.
siRNA, shRNA, and cDNA plasmids
Specific siRNA oligonucleotides against p70S6K 
(5’-GACAAAAUCCUCAAAUGUA-3’), P-cadherin 
(5’-GAGGGUGUCUUCGCUGUAG-3’), β1 integrin 
(5’-CCACAGACA UUUACAUUAA-3’), ST6Gal-I 
(5’-ACUCAGAUAUCCCAAAGUG-3’), p120-catenin 
(5’-UAGCUGACCUCCUGACUAA-3’), β-catenin 
(5’-AAGUCCUGUAUGAGUGGG AAC-3’), 
and nonspecific duplex oligo 
(5’-GGCTACGTCCAGGAGCGCA-3’) were obtained 
from Dharmacon (Lafayette, CO, USA). Transfection 
was performed using siLentFect (Bio-Rad, Hercules, 
CA, USA) according to the manufacturer’s procedures. 
To stably attenuate expression of p70S6K, β1 integrin, and 
P-cadherin, we infected cells with lentivirus containing 
p70S6K shRNA, β1 integrin shRNA or P-cadherin shRNA, 
or nonspecific shRNA as a control. Lentivrus-infected 
cells were selected for 72 hours in medium containing 
1 μg/ml puromycin (Invitrogen, San Diego, CA, USA). 
To ectopically express active p70S6K (D3E-E389) in 
CaOV-3 cells, we used a myc-tagged cDNA encoding 
the constitutively active p70S6K (generously given 
by Dr. George Thomas, Genome Research Institute, 
University of Cincinnati, OH, USA).
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Cancer spheroid adhesion assays
For measurement of adhesion to human peritoneal 
mesothelial cells, fluorescent-labeled spheroids were 
overlaid onto a monolayer of confluent primary human 
mesothelial cells coated on a 24-well plate and allowed 
to attach for 1 to 5 h before counting. For measurement 
of adhesion to ECM components, plates were first coated 
with fibronectin, laminin, vitronectin and collagen I 
(10 μg/ml) according to the manufacturer’s instructions 
(BD Biosciences, San Jose, CA, USA), spheroids were 
then added and allowed to attach for 1 to 5 h before 
counting. For the inhibition experiments, spheroids were 
pretreated with a neutralizing antibody to β1 integrin 
(clone JB1A; 1:100) (Chemicon, Chandlers Ford, UK) 
at 37oC for 30 min prior to incubation with mesothelial 
cells or the different ECM components. The total number 
of spheroids in each well was counted prior to removal 
of nonadherent spheroids. Nonadherent spheroids were 
removed by gentle washing with PBS. The remaining 
adhered spheroids were fixed and counted. The percentage 
of adhered spheroid was calculated by dividing the 
number of spheroids adhering on the mesothelium or ECM 
components by the total number of spheroids in each well 
before washing.
Reverse transcription-PCR
Total RNA was isolated using Trizol (Invitrogen) 
according to the manufacturer’s instructions. Total 
RNA (500 ng) was reverse transcribed using a First-
strand Reverse Transcription Kit (Invitrogen), and PCR 
was performed with a set of primers: ST6Gal-I, sense 
5’- TATCGTAAGCTGCACCCCAATC-3’, anti-sense 
5’-TTAGCAGTGAATG GTCCGGAAG-3’; and β-actin, 
sense 5’-TCACCGAGGCCCCTCTGAACCCTA-3’, 
anti-sense 5’-GGCAGTAATCTCCTTCTGCATCCT-3’. 
The number of amplification cycles, during which the 
PCR product formation was limited by the template 
concentration was determined in pilot experiments. The 
mRNA levels of target genes were normalized to that of 
β-actin.
Western blotting
Cells were harvested in SDS sample buffer (65 mM 
Tris-Cl pH 6.8, 2% SDS, 10% glycerol) supplemented 
with protease inhibitors (1 μg/ml aprotinin, 1 μg/ml 
leupeptin, 1 μg/ml pepstatin A, 1 mM phenylmethyl 
sulfonyl), 1 mM sodium orthovanadate and 1 mM sodium 
fluoride) and quantified using a DC protein assay kit 
(Bio-Rad). Equal amounts of protein were separated on 
SDS-polyacrylamide gels and transferred to nitrocellulose 
membrane. Membranes were then blocked and probed 
with the following primary antibodies: anti-c-myc (clone 
9E10; 1:1,500), anti-phospho-p70S6K (Thr389; 1:1,000), 
anti-p70S6K (1:1,000), anti-phospho-S6 (Ser235/236; 
1:1,000), anti-S6 (1:1,000) (Cell Signaling, Beverley, MA, 
USA), anti-β1 integrin (1:1,000) (Chemicon, Chandlers 
Ford, UK), anti-β-catenin (1:2,000), anti-p120ctn (1:1,000), 
anti-P-cadherin (1:1000) (Transduction Laboratories, 
Lexington, KY, USA) and anti-β-actin (1:2,000) (Sigma, 
St Louis, MO, USA). Western blot membranes were 
visualized using an enhanced chemiluminescent substrate 
for detection of horseradish peroxidase (Amersham, Little 
Chalfont, UK).
Mouse model of ovarian cancer metastasis
4-6 week-old female NOD SCID mice (Charles 
River Laboratories, Wilmington, MA) were used (n = 
3 per group), and the experiment was conducted twice. 
1x107 cells from the spheroid cultures were suspended in 
0.1 ml Hanks’ Balanced salt solution and were injected 
intraperitoneally into the peritoneal cavity. The mice were 
sacrificed and the numbers of disseminated tumor nodules 
within the peritoneal cavity were counted. All animal 
studies were performed using protocols approved by the 
University of Hong Kong Institutional Animal Care and 
Use Committee.
Statistical analyses
P values were based upon Student’s t test using 
GraphPad Prism (San Diego, CA, USA). P < 0.05 was 
considered to be statistically significant on the basis of at 
least three independent sets of experiments.
ACKNOWLEDGEMENTS
This research was supported by the Hong Kong 
Research Grant Council grants 782111 and 17122014 
(to ASTW); ASTW is a recipient of the Croucher Senior 
Research Fellowship.
Conflict of interest
The authors declare that they have no conflicts of 
interest.
REFERENCES
1. Siegel R, Naishadham D and Jemal A. Cancer statistics, 
2012. CA Cancer J Clin. 2012; 62:10–29.
2. Ip CK and Wong AS. Exploiting p70 S6 kinase as a  target 
for ovarian cancer. Expert Opin Ther Targets. 2012; 
16:619–630.
3. Altomare DA, Wang HQ, Skele KL, De Rienzo A, 
 Klein-Szanto AJ, Godwin AK and Testa JR. AKT and 
mTOR phosphorylation is frequently detected in ovarian 
cancer and can be targeted to disrupt ovarian tumor cell 
growth. Oncogene. 2004; 23:5853–5857.
Oncotarget9148www.impactjournals.com/oncotarget
4. Zhou HY and Wong AST. Activation of p70(S6K) induces 
expression of matrix metalloproteinase 9 associated with 
hepatocyte growth factor-mediated invasion in human 
 ovarian cancer cells. Endocrinology. 2006; 147:2557–2566.
5. Castellvi J, Garcia A, Rojo F, Ruiz-Marcellan C, Gil A, 
Baselga J and Cajal SRY. Phosphorylated 4E binding 
 protein 1: A hallmark of cell signaling that correlates with 
 survival in ovarian cancer. Cancer. 2006; 107:1801–1811.
6. Pon YL, Zhou HY, Cheung ANY, Ngan HYS and 
Wong AST. p70 S6 kinase promotes epithelial to mesen-
chymal transition through Snail induction in ovarian cancer 
cells. Cancer Res. 2008; 68:6524–6532.
7. Hynes RO. Integrins: bidirectional, allosteric signaling 
machines. Cell. 2002; 110:673–687.
8. Sundfeldt K. Cell-cell adhesion in the normal ovary and 
ovarian tumors of epithelial origin; an exception to the rule. 
Mol Cell Endocrinol. 2003; 202:89–96.
9. Elmasri WM, Casagrande G, Hoskins E, Kimm D and 
Kohn EC. Cell adhesion in ovarian cancer. Cancer Treat 
Res. 2009; 149:297–318.
10. Sowter HM, Corps AN and Smith SK. Hepatocyte growth 
factor (HGF) in ovarian epithelial tumour fluids stimulates 
the migration of ovarian carcinoma cells. Int J Cancer. 
1999; 83:476–480.
11. Sawada K, Radjabi AR, Shinomiya N, Kistner E, Kenny H, 
Becker AR, Turkyilmaz MA, Salgia R, Yamada SD, 
Vande Woude GF, Tretiakova MS and Lengyel E. c-Met 
overexpression is a prognostic factor in ovarian cancer and 
an effective target for inhibition of peritoneal dissemination 
and invasion. Cancer Res. 2007; 67:1670–1679.
12. Wong AS, Pelech SL, Woo MM, Yim G, Rosen B, Ehlen T, 
Leung PC and Auersperg N. Coexpression of hepatocyte 
growth factor-Met: an early step in ovarian carcinogenesis? 
Oncogene. 2001; 20:1318–1328.
13. Wong AST, Roskelley CD, Pelech S, Miller D, Leung PCK 
and Auersperg N. Progressive changes in Met-dependent 
signaling in a human ovarian surface epithelial model 
of malignant transformation. Exp Cell Res. 2004; 
299:248–256.
14. Moser TL, Pizzo SV, Bafetti LM, Fishman DA and 
Stack MS. Evidence for preferential adhesion of ovarian 
epithelial carcinoma cells to type I collagen mediated by 
the alpha2beta1 integrin. Int J Cancer. 1996; 67:695–701.
15. Wilson AP. Mesothelial cells stimulate the anchorage-
independent growth of human ovarian tumour cells. 
Br J Cancer. 1989; 59:876–882.
16. Tozer EC, Hughes PE and Loftus JC. Ligand binding and 
affinity modulation of integrins. Biochem Cell Biol. 1996; 
74:785–798.
17. Bellis SL. Variant glycosylation: an underappreciated 
 regulatory mechanism for beta1 integrins. Biochim Biophys 
Acta. 2004; 1663:52–60.
18. Semel AC, Seales EC, Singhal A, Eklund EA, Colley KJ 
and Bellis SL. Hyposialylation of integrins stimulates the 
activity of myeloid fibronectin receptors. J Biol Chem. 
2002; 277:32830–32836.
19. Seales EC, Jurado GA, Singhal A and Bellis SL. Ras 
oncogene directs expression of a differentially sialylated, 
functionally altered beta1 integrin. Oncogene. 2003; 
22:7137–7145.
20. Shaw TJ, Senterman MK, Dawson K, Crane CA and 
Vanderhyden BC. Characterization of intraperitoneal, 
orthotopic, and metastatic xenograft models of human 
 ovarian cancer. Mol Ther. 2004; 10:1032–1042.
21. Cheung LW, Mak AS, Cheung AN, Ngan HY, Leung PC 
and Wong AS. P-cadherin cooperates with insulin-like 
growth factor-1 receptor to promote metastatic signaling of 
gonadotropin-releasing hormone in ovarian cancer via p120 
catenin. Oncogene. 2011; 30:2964–2974.
22. Gumbiner BM. Regulation of cadherin-mediated adhesion 
in morphogenesis. Nat Rev Mol Cell Biol. 2005; 6:622–634.
23. Takeichi M. Morphogenetic roles of classic cadherins. Curr 
Opin Cell Biol. 1995; 7:619–627.
24. Burleson KM, Hansen LK and Skubitz AP. Ovarian 
 carcinoma spheroids disaggregate on type I collagen and 
invade live human mesothelial cell monolayers. Clin Exp 
Metastasis. 2004; 21:685–697.
25. Muller-Klingspor V, Hefler L, Obermair A, Kaider A, 
Breitenecker G, Leodolte S and Kohlberger P. Prognostic 
value of beta1-integrin (=CD29) in serous adenocarcinomas 
of the ovary. Anticancer Res. 2001; 21:2185–2188.
26. Mitra AK, Sawada K, Tiwari P, Mui K, Gwin K and 
Lengyel E. Ligand-independent activation of c-Met by 
fibronectin and alpha(5)beta(1)-integrin regulates ovar-
ian cancer invasion and metastasis. Oncogene. 2011; 
30:1566–1576.
27. Cheung LW, Leung PC and Wong AS. Cadherin switch-
ing and activation of p120 catenin signaling are mediators 
of gonadotropin-releasing hormone to promote tumor cell 
migration and invasion in ovarian cancer. Oncogene. 2010; 
29:2427–2440.
28. Buczek-Thomas JA, Chen N and Hasan T. 
 Integrin-mediated adhesion and signalling in ovarian cancer 
cells. Cell Signal. 1998; 10:55–63.
29. Ouyang M, Lu S, Kim T, Chen CE, Seong J, Leckband DE, 
Wang F, Reynolds AB, Schwartz MA and Wang Y. 
N-cadherin regulates spatially polarized signals through 
 distinct p120ctn and beta-catenin-dependent signalling 
pathways. Nat Commun. 2013; 4:1589.
30. Mukoyama Y, Utani A, Matsui S, Zhou S, Miyachi Y 
and Matsuyoshi N. T-cadherin enhances cell-matrix 
adhesiveness by regulating beta1 integrin trafficking in 
cutaneous squamous carcinoma cells. Genes Cells. 2007; 
12:787–796.
31. Marsden M and DeSimone DW. Integrin-ECM interactions 
regulate cadherin-dependent cell adhesion and are required 
for convergent extension in Xenopus. Curr Biol. 2003; 
13:1182–1191.
Oncotarget9149www.impactjournals.com/oncotarget
32. Martinez-Rico C, Pincet F, Thiery JP and Dufour S. 
Integrins stimulate E-cadherin-mediated intercellular adhe-
sion by regulating Src-kinase activation and actomyosin 
contractility. J Cell Sci. 2010; 123:712–722.
33. Yano H, Mazaki Y, Kurokawa K, Hanks SK, Matsuda M 
and Sabe H. Roles played by a subset of integrin signaling 
molecules in cadherin-based cell-cell adhesion. J Cell Biol. 
2004; 166:283–295.
34. Niessen CM and Gottardi CJ. Molecular components 
of the adherens junction. Biochim Biophys Acta. 2008; 
1778:562–571.
35. Dall’Olio F. The sialyl-alpha2,6-lactosaminyl-structure: 
biosynthesis and functional role. Glycoconj J. 2000; 
17:669–676.
36. Le Marer N, Laudet V, Svensson EC, Cazlaris H, 
Van Hille B, Lagrou C, Stehelin D, Montreuil J, Verbert A 
and Delannoy P. The c-Ha-ras oncogene induces increased 
expression of beta-galactoside alpha-2, 6- sialyltransferase 
in rat fibroblast (FR3T3) cells. Glycobiology. 1992; 
2:49–56.
37. Svensson EC, Soreghan B and Paulson JC. Organization 
of the beta-galactoside alpha 2,6-sialyltransferase gene. 
Evidence for the transcriptional regulation of terminal gly-
cosylation. J Biol Chem. 1990; 265:20863–20868.
38. Vandamme V, Cazlaris H, Le Marer N, Laudet V, 
Lagrou C, Verbert A and Delannoy P. Comparison of sialyl- 
and alpha-1,3-galactosyltransferase activity in NIH3T3 cells 
transformed with ras oncogene: increased beta-galactoside 
alpha-2,6-sialyltransferase. Biochimie. 1992; 74:89–99.
39. Christie DR, Shaikh FM, Lucas JAt, Lucas JA 3rd and 
Bellis SL. ST6Gal-I expression in ovarian cancer cells pro-
motes an invasive phenotype by altering integrin glycosyl-
ation and function. J Ovarian Res. 2008; 1:3.
40. Dall’Olio F and Chiricolo M. Sialyltransferases in cancer. 
Glycoconj J. 2001; 18:841–850.
41. Schultz MJ, Swindall AF, Wright JW, Sztul ES, Landen CN 
and Bellis SL. ST6Gal-I sialyltransferase confers cisplatin 
resistance in ovarian tumor cells. J Ovarian Res. 2013; 6:25.
42. Tang MK, Zhou HY, Yam JW and Wong AS. c-Met over-
expression contributes to the acquired apoptotic resistance 
of nonadherent ovarian cancer cells through a cross talk 
mediated by phosphatidylinositol 3-kinase and extracellular 
signal-regulated kinase 1/2. Neoplasia. 2010; 12:128–138.
43. Zietarska M, Maugard CM, Filali-Mouhim A, 
 Alam-Fahmy M, Tonin PN, Provencher DM and 
 Mes-Masson AM. Molecular description of a 3D in vitro 
model for the study of epithelial ovarian cancer (EOC). Mol 
Carcinog. 2007; 46:872–885.
44. Mabuchi S, Altomare DA, Cheung M, Zhang L, 
Poulikakos PI, Hensley HH, Schilder RJ, Ozols RF and 
Testa JR. RAD001 inhibits human ovarian cancer cell 
proliferation, enhances cisplatin-induced apoptosis, and 
 prolongs survival in an ovarian cancer model. Clinical 
cancer research : an official journal of the American 
Association for Cancer Research. 2007; 13:4261–4270.
45. Mabuchi S, Altomare DA, Connolly DC, Klein-Szanto A, 
Litwin S, Hoelzle MK, Hensley HH, Hamilton TC and 
Testa JR. RAD001 (Everolimus) delays tumor onset and 
progression in a transgenic mouse model of ovarian cancer. 
Cancer Res. 2007; 67:2408–2413.
46. Takano M, Kikuchi Y, Kudoh K, Goto T, Furuya K, 
Kikuchi R, Kita T, Fujiwara K, Shiozawa T and Aoki D. 
Weekly administration of temsirolimus for heavily 
 pretreated patients with clear cell carcinoma of the ovary: 
a report of six cases. International journal of clinical 
 oncology. 2011; 16:605–609.
47. Santiskulvong C, Konecny GE, Fekete M, Chen KY, 
Karam A, Mulholland D, Eng C, Wu H, Song M and 
Dorigo O. Dual targeting of phosphoinositide 3-kinase and 
mammalian target of rapamycin using NVP-BEZ235 as a 
novel therapeutic approach in human ovarian carcinoma. 
Clinical cancer research : an official journal of the American 
Association for Cancer Research. 2011; 17:2373–2384.
48. Huynh H, Teo CC and Soo KC. Bevacizumab and 
 rapamycin inhibit tumor growth in peritoneal model of 
human ovarian cancer. Molecular cancer therapeutics. 2007; 
6:2959–2966.
49. Piha-Paul SA, Wheler JJ, Fu S, Levenback C, Lu K, 
Falchook GS, Naing A, Hong DS, Tsimberidou AM and 
Kurzrock R. Advanced gynecologic malignancies treated 
with a combination of the VEGF inhibitor bevacizumab 
and the mTOR inhibitor temsirolimus. Oncotarget. 2014; 
5:1846–1855.
50. Comas M, Toshkov I, Kuropatwinski KK, Chernova OB, 
Polinsky A, Blagosklonny MV, Gudkov AV and Antoch 
MP. New nanoformulation of rapamycin Rapatar extends 
lifespan in homozygous p53-/- mice by delaying carcino-
genesis. Aging. 2012; 4:715–722.
51. Komarova EA, Antoch MP, Novototskaya LR, 
Chernova OB, Paszkiewicz G, Leontieva OV, 
Blagosklonny MV and Gudkov AV. Rapamycin extends 
lifespan and delays tumorigenesis in heterozygous p53+/- 
mice. Aging. 2012; 4:709–714.
52. Leontieva OV, Novototskaya LR, Paszkiewicz GM, 
Komarova EA, Gudkov AV and Blagosklonny MV. 
Dysregulation of the mTOR pathway in p53-deficient mice. 
Cancer biology & therapy. 2013; 14:1182–1188.
53. Romero I and Bast RC Jr. Minireview: human ovarian 
 cancer: biology, current management, and paths to person-
alizing therapy. Endocrinology. 2012; 153:1593–1602.
54. Iwanicki MP, Davidowitz RA, Ng MR, Besser A, 
Muranen T, Merritt M, Danuser G, Ince TA and Brugge JS. 
Ovarian cancer spheroids use myosin-generated force to 
clear the mesothelium. Cancer Discov. 2011; 1:144–157.
55. Yung S, Li FK and Chan TM. Peritoneal mesothelial cell 
culture and biology. Perit Dial Int. 2006; 26:162–173.
